Saudi Chemical Posts SAR 167.78M Net Profit in the Six Months 2026
CHEMICAL 2230.SA | 0.00 |
On 2026-08-02 08:03:41 (Saudi Time), Saudi Chemical Co. announced its Interim financial results for the six months ended on June 30, 2026.
| Element List | Current Quarter | Similar quarter for previous year | %Change | Previous Quarter | % Change |
|---|---|---|---|---|---|
| Sales/Revenue | 1,842,321 | 1,765,623 | 4.343 | 1,726,730 | 6.694 |
| Gross Profit (Loss) | 207,764 | 208,896 | -0.541 | 203,682 | 2.004 |
| Operational Profit (Loss) | 110,389 | 109,364 | 0.937 | 112,491 | -1.868 |
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 80,569 | 69,460 | 15.993 | 87,207 | -7.611 |
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 80,569 | 69,460 | 15.993 | 87,207 | -7.611 |
| All figures are in (Thousands) Saudi Arabia, Riyals | |||||
| Element List | Current Period | Similar period for previous year | %Change |
|---|---|---|---|
| Sales/Revenue | 3,569,051 | 3,409,341 | 4.684 |
| Gross Profit (Loss) | 411,446 | 428,814 | -4.05 |
| Operational Profit (Loss) | 222,880 | 228,027 | -2.257 |
| Net Profit (Loss) Attributable to Shareholders of the Issuer | 167,776 | 151,742 | 10.566 |
| Total Comprehensive Income Attributable to Shareholders of the Issuer | 167,776 | 151,742 | 10.566 |
| Total Shareholders Equity (after Deducting Minority Equity) | 2,466,310 | 2,200,520 | 12.078 |
| Profit (Loss) per Share | 0.2 | 0.18 | |
| All figures are in (Thousands) Saudi Arabia, Riyals | |||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Thousands) Saudi Arabia, Riyals | |||
Year-on-Year Performance Drivers
For H1 2026, Saudi Chemical Company Holding's sales/revenue rose 4.684% YoY to SAR 3,569.05 million (SAR 3.57 million after conversion) from SAR 3,409.34 million, primarily driven by higher sales volumes across its business segments. Net profit attributable to shareholders grew 10.566% YoY to SAR 167.78 million from SAR 151.74 million, mainly due to lower expected credit loss on trade receivables, reduced finance costs stemming from a significantly lower cost of debt, and revaluation gains on derivative financial instruments related to interest rate exposure, partially offset by higher Zakat and tax provisions.
Quarter-on-Quarter Performance Drivers
QoQ revenue rose 6.69% to SAR 1,842.32 million (SAR 1,726.73 million in Q1 2026), driven by higher sales volumes led by continued growth in the Healthcare and Explosives segments. Despite gross profit improving 2.004% QoQ to SAR 207.76 million, net profit attributable to shareholders declined 7.611% QoQ to SAR 80.57 million (from SAR 87.21 million in Q1 2026), primarily due to an increase in expected credit loss on trade receivables and higher Zakat and tax provisions, partially offset by a revaluation gain on derivative financial instruments related to interest rate exposure.
Other Items
The external auditor issued an unmodified conclusion with no additional comments or reservations noted. A reclassification of comparative figures was made, with SAR 16.99 million reclassified from selling and marketing expenses to cost of revenues during H1 2025 to conform with the current period's presentation. Net cash generated from operating activities reached SAR +182.1 million during H1 2026, compared to a net cash outflow of SAR -50.4 million in H1 2025. No material risks, going concern uncertainties, accumulated losses, or debt covenant breaches were disclosed in this announcement.
Original announcement:
https://www.saudiexchange.sa/wps/portal/saudiexchange/newsandreports/issuer-news/issuer-announcements/issuer-announcements-details/?anId=97130&anCat=1&cs=2230&locale=arImportant Notice: The announcement information and market data in this report are sourced directly from the Saudi Exchange (Tadawul). This summary is generated by Sahm’s proprietary AI model for informational purposes only. While we strive for accuracy, it should not be construed as financial advice or an investment recommendation.